Business in Brief
Consumer unit sales, stem cell therapy approvals and beating counterfeits with blockchain… what’s new for pharma in business?
Stephanie Sutton |
Deals & acquisitions
- GlaxoSmithKline is acquiring Novartis’ consumer health business for $13 billion. The business was initially a joint venture between the two companies and includes products such as Nicotinell nicotine patches, Panadol headache tablets and Sensodyne toothpaste.
- Pfizer has also been looking for a deal regarding its own consumer health business. The company has been assessing options since October 2017. Potential bidders included GSK and Reckitt Benckiser, but both pulled out in March. Now, Pfizer has been reported by many to be in talks with Procter & Gamble.
- Takeda has confirmed that it is considering an offer for Shire with the aim of boosting its footprint in gastroenterology, oncology and neuroscience. No approach has yet been made to Shire’s board and Takeda stressed that the offer was at a “preliminary and exploratory stage”.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine